No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 736 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Man Walks Entire Continent To Spread Awareness About Mental Health &... January 16, 2022 InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of... May 5, 2025 How will new cancer medicines be approved in the future? December 2, 2021 Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... May 24, 2023 Load more HOT NEWS How Pelvic Floor Therapy Can Help People With Prostate Cancer and... FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... Triple negative breast cancer drug given initial ‘no’ for NHS in... 3 Steps to Making the Right Decisions for You During Cancer:...
